{"schema_version":"secwatch.filing_event.v1","accession":"0000950170-24-011954","form_type":"8-K","ticker":"VIVS","cik":"0001497253","company_name":"VivoSim Labs, INC.","filed_at":"2024-02-07T23:59:59+00:00","discovered_at":"2026-05-14T18:03:24.337390+00:00","generated_at":"2026-06-06T06:54:58.084013+00:00","sec_items":["7.01","9.01"],"event_type":"other_material","sentiment":"neutral","materiality_score":0.5,"calibrated_materiality_score":0.5,"confidence":"high","headline":"Organovo presents FXR314 data in 3D models of Crohn's disease and ulcerative colitis","bullets":["FXR314, a clinical-stage FXR agonist, tested in human primary cell 3D models.","Data presented at Crohn's & Colitis Congress, Jan 25-27, 2024 in Las Vegas.","Presentation covers models for both Crohn's disease and ulcerative colitis.","Presentation current as of January 25, 2024; furnished as Exhibit 99.1."],"urls":{"canonical":"https://secwatch.observer/filing/0000950170-24-011954","json":"https://secwatch.observer/filing/0000950170-24-011954.json","markdown":"https://secwatch.observer/filing/0000950170-24-011954.md","text":"https://secwatch.observer/filing/0000950170-24-011954.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/1497253/000095017024011954/0000950170-24-011954-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1497253/000095017024011954/onvo-20240207.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-06-06T06:54:58.084013+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}